Saar Gill, MD
Concurrent treatment with CTL-119 cell therapy and ibrutinib (Imbruvica) led to complete marrow clearance of leukemic cells in 8 of 9 evaluable patients with heavily pretreated or genetically high-risk chronic lymphocytic leukemia (CLL), results of a pilot study showed.
“Another important aspect of what we showed in this study is the relative lack of toxicity,” he added. “Everyone gets CRS but no one gets severe CRS. No patient required tocilizumab. Some of these patients were treated exclusively as outpatients. It is an advance, as far as I see.”
Gill S, Frey NV, Hexner EO, et al. CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL. J Clin Oncol 35, 2017 (suppl; abstr 7509).
... to read the full story